Cereno Scientific's nomination committee proposes Joakim Söderström as new chairman of the board

Cereno Scientific (XSAT: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the nomination committee's proposed resolutions for the 2023 annual general meeting include the new election of Joakim Söderström as chairman of the board. The nomination committee also proposes that the board be consolidated to include five members and no deputies.

“Personally, it is very exciting to see how the drug candidate CS1, which my research group discovered had very interesting cardiovascular effects and around which the company was founded, is now in a Phase II study with results expected at the end of the year. Cereno's journey is now in front of a new phase and preparations for the company to have more clinical projects within 1-2 years have begun. The work that the nomination committee has carried out during the autumn and spring has therefore been mainly focused on consolidating the board in order to best support the company and the further development of the company's drug candidates,” says Sverker Jern, co-founder of Cereno and chairman of the nomination committee.

The nomination committee has chosen to consolidate the board to five members and proposes re-election of board members Sverker Jern, Anders Svensson and Lena Mårtensson as well as new election of Jonas Faijerson Säljö (former board deputy) and Joakim Söderström. Catharina Bäärnhielm and Klementina Österberg have declined re-election. Furthermore, Niklas Bergh, Björn Dahlöf and Rein Piir are leaving the board. The board will continue a close collaboration with the company's management, above all with Sten R. Sörensen, CEO, and with Björn Dahlöf, Cereno's Chief Medical Officer (CMO), Chief Scientific Officer (CSO) and Head of Clinical Development.

“I am proud to have been part of the journey Cereno has made from a small research company born out of academic research at the University of Gothenburg to an established biotech company with three promising drug candidates in cardiovascular diseases. I am now handing over the chairman's baton to the incoming chairman who, together with the company's management and board, will continue to work on developing Cereno's strong project portfolio in cardiovascular diseases,” says Catharina Bäärnhielm, outgoing chairman of the board.

Joakim Söderström, proposed new chairman of the board comments, “I am happy and honored to be nominated as chairman of the board for Cereno. The company is well managed with very promising research and a strong scientific focus that has been validated through the unique collaboration with the global healthcare company Abbott and research partner University of Michigan. With its clinical drug candidate CS1 in a Phase II study and two promising preclinical development programs, the future looks bright.”

Joakim Söderström is an entrepreneur and biotech investor with experience as CEO, board member, and chairman. Joakim is currently the CEO of Svensk Bakgrundsanalys AB, CEO and board member of Quod Opto AB and J-TAC AB. Joakim was previously the CEO of SäkerhetsBranschen and Vice President of Euroalarm. Moreover, Joakim has previously held multiple managerial positions within the Swedish Police Authority.

For further information, please contact:

Jonas Fogelberg, Interim CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.